LP-005

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameLP-005
Drug Alias NameLP-005RX-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionComplement C3 inhibitorsComplement C5 inhibitors
TargetsComplement C3Complement C5
Therapy Area/IndicationsC3 glomerulopathyComplement-Mediated DiseasesThrombotic Microangiopathies +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLongbio Pharma (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGeneCraft IncLongbio Pharma (Suzhou) Co LtdProbio Technology HK Ltd
Inactive CompaniesN/A
Active IndicationsC3 glomerulopathyComplement-Mediated DiseasesThrombotic Microangiopathies +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A